Marie Skłodowska-Curie ITN-European Joint Doctorate
MOGLYNET-PhD programme in drug discovery and development
The Horizon 2020 MSCA joint doctoral project MoGglyNet (“Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study”) is running by a Consortium of Universities in cooperation with Pharma Industries and Associations. The programme was established with the aim of providing 12 Early Stage Researchers with innovative PhD trainings in Drug Discovery and Development.
The MOGLYNET PhD programme aims to define a new joint PhD educational model in Drug Discovery and Development and to promote institutional cooperation and mobility.
An active contribution of Industry in training activities is an important feature of the programme. The research methodologies and approaches proposed by the MOGLYNET consortium are strongly multidisciplinary and will involve a number of different state-of-the-art technologies and methodologies. These includes computational chemistry, chemical synthesis, bioanalytics, biophysics, in vitro biological evaluations, in vivo studies, imaging, metabolomics, proteomics, and oxidative stress studies.
WE SEE THE FUTURE
MOGLYNET IN NUMBERS
WHAT WE THINK ABOUT MOGLYNET
Dr.ssa Anni Svala
The non-academic contribution provides the way forward to help academia in meeting the educational needs of pharmaceutical industry.
Prof.ssa Marina Carini
The exposure of recruited researchers to different environments is specifically designed to integrate and complement the sectorial knowledge of the fellow allowing the creation of a common knowledge and language for ESRs.
Dr. Stefano Bellosta
Synergy between all the participants is fundamental to reach the goals planned by MOGLYNET programme.
Prof. Matteo Zanda
MOGLYNET EJD stems from six Doctoral Courses/Schools at the five beneficiary institutions providing research and training in the field of drug discovery and health. A double degree in Drug Discovery and Development will be delivered by two Accademic beneficiaries.
Dr.ssa Mirela Delibegovic
The research methodologies and approaches proposed by the MOGLYNET consortium are strongly multidisciplinary (from molecular modelling to in vivo studies) and will involve a number of different state-of-the-art technologies and methodologies.
Prof. Guido De Meyer
We are a consortium of excellence in the atherosclerosis field. The research strategy proposed by MOGLYNET to takle atherosclerosis, which is a major unmet medical need, is higly original and innovative.
Prof. Paul Quax
Atherosclerotic cardiovascular disease is a disease of aging and is the major cause of death in the western world and for this reason there is a strong high need for additional pharmacological interventions.
Prof. Francesca Clerici
The European Commission has identified active and healthy aging as a major societal challenge common to all European countries, and an area which presents considerable potential for Europe to lead the world in providing innovative responses to this challenge.
Prof. Maria Luisa Gelmi
The transfer of “what” a researcher know in “how” to realize this in a complex system related to the drug is not trivial and requires a wide overall view of the problem. The mission of MOGLYNET is to define a joint doctorate educational training model where Academia and Industry Join their forces to reach this target.
We are the MOGLYNET-PhD programme in drug discovery and development.
The Horizon 2020 MSCA joint doctoral project MOGLYNET (“Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study”) is run by a Consortium of Universities in cooperation with Industries and Associations operating in the Pharma sector with the aim to offer an innovative PhD level training in Drug Discovery and Development to 12 Early Stage Researchers